No. HT942526RCRPIDA · Defense Health Agency Contracting Activity - DHACA
DoW Rare Cancers Idea Development Award
Not reimbursement-only
“"The funding instrument for awards made under the program announcement will be grants (31 USC 6304)."” — From the announcement
At a glance
AI summaryThis program funds rare cancers research ideas that are ready for development and could lead to high-impact findings, new discoveries, or better outcomes. Eligible applicants include extramural and intramural U.S. Department of War organizations, including foreign and domestic, for-profit and nonprofit, and public or private entities; independent investigators at eligible organizations may serve as principal investigator. The program expects about 15 awards, with total costs capped at $490,000 per award and a maximum period of performance of 3 years. Cost sharing is not required. The research must involve cancers affecting six or fewer people per 100,000 per year in the United States, and clinical trials are not allowed.
AI-generated summary — verify against the announcement
What it funds
Official description from grants.gov
Summary: The fiscal year 2026 (FY26) Rare Cancers Research Program (RCRP) Idea Development Award (IDA) promotes ideas that are ready for further development and have the potential to yield high-impact findings and new avenues of investigation. Distinctive Features: The RCRP encourages applicants to include an exploratory aim or sub-aim to support any necessary discovery-driven research. Preliminary data with disease-specific rationale are required. However, these data do not necessarily need to originate from studies of the proposed rare cancer type(s)/subtype(s) under study. Research should have high potential impact on rare cancers and the patient community.
Who can apply
- Unrestricted